-
AFT
(AFT製藥有限公司旗下品牌)
鎖定
AFT品牌歷史
2004年 成立澳大利亞分部。
同年,AFT開始進行藥物開發工作
2008年 AFT開始佈局東南亞市場,三種自有產品也在東南亞達成對外授權。
同年12月,AFT在馬來西亞推出第一批產品
2012年 AFT集團銷售額增至5000萬新西蘭元。
同年,AFT在澳大利亞和新西蘭推出無防腐劑的 HYLO-FRESH 和 HYLO-FORTE 眼藥水,
2018年 Maxigesic® PE 在新西蘭推出含有撲熱息痛、布洛芬和脱氧腎上腺素的專利組合,可提供感冒、流感和鼻竇緩解的三重作用
2020年 AFT在澳大利亞和新西蘭推出 Maxigesic® IV;國際許可交易繼續增長
推出眼部護理產品系列新產品NovaTears® + Omega-3
AFT品牌故事
Hartley博士和Marree Atkinson在1997年共同創立了AFT。Hartley博士深信,在醫藥領域,科技創新和產品研發是推動產業發展的最有力的推動力,“科技創新決定一切”。“開發能夠幫助人們的創新產品”,成為AFT最重要的企業願景。2004年AFT開始開發Maxigesic (撲熱息痛和布洛芬的專利鎮痛組合),並在次年開始在澳大利亞進行藥品銷售。2009年-2014年,Maxigesic先後在新西蘭和澳大利亞註冊並開始銷售,Maxigesic® (專利鎮痛藥) 成為澳洲排名第一的止痛藥品牌,佔據了澳大利亞40%市場份額。採用微囊脂質體新技術的補鐵劑,獨特的Lipo-Sachet維C水溶液,也相繼成為AFT明星產品。2014年,AFT 開始佈局東南亞市場,並於2015年開始IPO,以籌集資金追求更積極的研發主導型增長戰略。
[2-3]
AFT產品組合
AFT的產品組合包括許可經營產品,藥品、品牌藥品和非專利藥品。目前,AFT已推出超過150種產品,產品涵蓋:
護膚系列
Coco-Scalp®藥膏
消化排毒系列
DiaRelieve®腹瀉藥
保健品系列
Ferro Lipo-Sachets® 鐵補充劑
Histaclear® 季節性和常年性過敏性鼻炎藥
Lipo-Sachets® 兒童利鉑維生素 C
Lipo-Sachets® 利鉑維生素C
Lipo-Sachets® 利鉑維生素 D
Maxiclear® Cold & Flu Relief/Sinus & Pain Relief 感冒和流感藥
Maxiclear® Cold & Nasal Relief/Hayfever & Sinus Relief 感冒藥,治療花粉症和鼻竇緩解
鎮痛系列
Maxigesic® 撲熱息痛和布洛芬雙效配方
其他系列
Crystawash® Extend泡沫免洗洗手液
Opti-Soothe® 無防腐劑眼瞼濕巾
AFT團隊成員
首席執行官:Dr Hartley Atkinson 哈特利·阿特金森博士
首席財務官:Malcolm Tubby馬爾科姆·塔比
首席科學官:Ioana Stanescu約阿娜·斯坦內斯庫
Ioana 全面負責 AFT 的研發工作。
法規事務經理:Vladimir Ilievski弗拉基米爾·伊利耶夫斯基
AFT品牌使命
AFT品牌口號
AFT品牌願景
AFT品牌價值觀
AFT科研能力
Atkinson HC, Begg EJ & Darlow BA. Drugs in human milk: Clinical and pharmacokinetic considerations in CLINICAL PHARMACOKINETICS DRUG DATA HANDBOOK Adis Press: Auckland.
Begg EJ, Atkinson HC & Darlow BA. Guide to Safety of Drugs in Breastfeeding in Averys Drug Treatment 4th edition, Adis International, Auckland
Atkinson, HC, Gopal YC & McKeown RH. The feasibility of licit production of morphine derivatives in New Zealand - codeine and pholcodine in particular. NZHPA conference proceedings Vol 2.
Atkinson HC. Chloroform use in oral medicine. NZ Med J 99, 555.
Begg EJ, Atkinson HC, Jeffery M & Taylor N. Comparison of computerized prediction of aminoglycoside dosage with dosage based on physician intuition. ASCEP conference proceedings - Monash, Victoria, Australia
[2]
Begg EJ, Atkinson HC & Gianarakis N. The pharmacokinetics of corticosteroid agents. Aust Med J 146, 37-41.
Atkinson HC & Begg EJ. The Christchurch hospital drug information service: organisation and an audit of the first 300 questions answered. NZ Med J, 100, 530-2
Atkinson HC& Begg EJ. Prediction of drug concentration in human skim milk from plasma protein binding and acid-base characteristics. Br J Clin Pharmac, 25, 495-503.
Atkinson HC & Dufful S. Prediction of drug loss from PVC infusion bags. NZHPA conference proceedings.
Atkinson HC, Begg EJ and Darlow BA. Drugs in human milk-pharmacokinetic considerations. Clin, Pharmcokinet. 14, 217-240.
Atkinson HC & Begg EJ. The binding of drug to major human milk proteins. Br J Clin Pharmac, 26, 107-109
Chapman MH, Woolner DF, Begg EJ, Atkinson HC& Sharman JR. Co-administered oral metoclopramide does not enhance the rate of absorption or oral diazepam. Anaesth Intens Care, 16, 202-205
Atkinson HC & Begg EJ. Relationship between human milk lipid: ultrafiltrate and octanol: water partition coefficients. J Pharm Sci, 77, 796-8
Begg EJ, Atkinson HC et al. Individualised aminoglycoside dosage based on pahrmacokinetic analysis is superior to dosage based on physician based intuition at achieving target plasma drug concentrations. Br J Clin Pharm, 28, 137-141
[2]
Atkinson HC, Chambers St & McGinlay AM. Antibiotic therapy costs. NZ Med J 102, 409-11
Atkinson HC & Begg EJ. Prediction of drug distribution into human milk from physicochemical characteristics. Clin Pharmacokinet 18(2) 151-167
Robson RA, Begg EJ, Atkinson HC, Saunders DA & Framton CM. Comparative effects of ciprofloxacin and lomefloxacin on the oxidative metabolism of theophylline. Br J Clin Pharm, 29, 491-3
Begg EJ & Atkinson HC. Partitioning of drugs into human milk. Annals of Med, 20(1), 51-5
Atkinson HC & Duffull SB. Prediction of drug loss from PVC Infusion bags. J Pharm 43.374-6
Hickling KG, Begg EJ, Perry RE, Atkinson HC & Sharman JR. Serum aminoglycoside clearance is predicted poorly by renal aminoglycoside clearance as by creatinine clearance in critically ill patients. Critical Care Med 19, 1041-7
Begg EJ, Atkinson HC & Duffull SB. Prospective eavaluation of a model for the prediction of milk:plasma drug concentrations from physicochemical characteristics. Br J Clin Pharmac 33, 501-6
Begg EJ & Atkinson HC. Modeling of the passage of drugs into milk. Pharmac & Ther 59, 301-310
Atkinson HC, Stanescu I, Anderson BJ. Increased phenylephrine plasma concentration when given in combination with acetaminophen. New England Journal of Medicine, 379:12
Atkinson HC, Stanescu I, Salem II, Potts AL, Anderson BJ. Increased bioavailability by co-administration of acetaminophen: results of four open-label, crossover pharmacokinetic trials in healthy volunteers. Eur. J. Clin. Pharmacol 71:771-772.
Atkinson HC, Stanescu I, Beasley CH, Salem II,Frampton C. A pharmacokinetic analysis of a novel fixed dose oral combination of paracetamol and ibuprofen, with emphasis on food effect. J. Bioequivalence & Bioavailability, 2015, 7:150-154
Atkinson HC, Stanescu I, Frampton C, Salem II,Beasley CH, Robson R. Pharmacokinetics and bioavailability of a fixed-dose combination of ibuprofen and paracetamol after intravenous and oral administration. Clin. Drug Investig.DOI 10.1007/s40261-015-0320-8
Atkinson HC, Potts AL, Anderson BJ. Potential cardiovascular adverse events when phenylephrine is combined with paracetamol: simulation and narrative review. Eur. J.Clin. Pharmacol. DOI 10.1007/s00228-015-1876-1
Atkinson HC, Currie J, Moodie J, Carson S, Evans S, Worthington J, Steenberg LJ, Bisley E, Frampton C. Combination paracetamol and ibuprofen for pain relief after oral surgery: a dose ranging study. Eur. J.Clin Pharmacol, DOI 10.1007?s00228-015-1827
Aitken P, Salem II, Stanescu I, Playne C, Atkinson HC. A single dose, four-way, open-label bioavailability study of oral acetaminophen and ibuprofen combinations (Maxigesic®) under both fasting and fed conditions. Journal of Bioequivalence & Bioavailability,Volume 10 (5):84-91.
Playne R, Anderson BJ, Frampton C, Stanescu I, Atkinson HC. Analgesic effectiveness,pharmacokinetics, and safety of a paracetamol/ibuprofen fixed-dose combination in children undergoing adenotonsillectomy: A randomized, single-blind, parallel group trial. Pediatric Anesthesia. 28:1087-1095.
Daniels SE, Atkinson HC, Stanescu I, Frampton C. Analgesic efficacy of an acetaminophen/ibuprofen fixed-dose combination in moderate to severe postoperative dental pain: A randomized, doublé-blind, parallel-group, placebo-controlled trial. Clinical Therapeutics/Volume 40, Number 10.
Aitken P, Stanescu I, Playne R, Zhang J, Frampton C, Atkinson HC. An integrated safety analysis of combined acetaminophen and ibuprofen (Maxigesic®/Combogesic®) in adults. Journal of Pain Research. Vol.12, 1-15.
[2]
Gottlieb IJ, Gilchrist N, Carson S, Stanescu I, Atkinson H. Extending the safety profile of the post-operative administration of an intravenous acetaminophen/ibuprofen fixed dose combination: An open-label, multi-center, single arm, multiple dose study. Biomedicine and Pharmacotherapy Vol 139: 111710.
Morse JD, Stanescu I, Atkinson HC, Anderson BJ. Population pharmacokinetic modelling of acetaminophen and ibuprofen: the influence of body composition, formulation and feeding in healthy adult volunteers. European Journal of Drug Metabolism and Pharmacokinetics.
Aitken P, Stanescu I, Boddington L, Mahon C, Fogarasi A, Liao Yi-Hua, Ivars M, Moreno-Artero E, Trauner D, DeRoos St, Jancic J, Nikolic M, Balazova P, Price HP, Hadzsiev K, Riney K, Stapleton S, Tollefson MM, Bauer D, Pinkova B, Atkinson H. A novel rapamycin cream formulation improves facial angiofibromas associated with tuberous sclerosis complex: a double-blind randomized placebo-controlled trial. Br.J. Dermatol 2023;00:1-11
[2]
- 參考資料
-
- 1. AFT .國家知識產權局[引用日期2023-12-12]
- 2. 品牌簡介 .官網[引用日期2023-12-12]
- 3. 今日大寒|讓健康守護你的冬日 .AFT製藥[引用日期2024-01-24]
- 詞條統計
-
- 瀏覽次數:次
- 編輯次數:17次歷史版本
- 最近更新: mf5uy0